Solid Biosciences Inc. Gain (Loss) on Derivative Instruments, Net, Pretax
Solid Biosciences Inc. (SLDB) reported Gain (Loss) on Derivative Instruments, Net, Pretax of -$850.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-08-06
- Solid Biosciences Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-06-30 was -$850.00K.
- Solid Biosciences Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-03-31 was -$1.65M.
- Solid Biosciences Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-12-31 was -$2.65M.
- Solid Biosciences Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-09-30 was -$850.00K.
- Solid Biosciences Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2025 was -$6.05M.
- Solid Biosciences Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2024 was -$4.75M.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$850.00K 10-Q · filed 2026-08-06 | -$2.50M 10-Q · filed 2026-08-06 | -$5.15M derived: sum of 3 quarters · filed 2026-08-06 | -$6.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.65M 10-Q · filed 2026-05-12 | -$4.30M derived: sum of 2 quarters · filed 2026-05-12 | -$5.15M derived: sum of 3 quarters · filed 2026-05-12 | -$6.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$3.50M derived: sum of 2 quarters · filed 2026-03-19 | -$4.40M derived: sum of 3 quarters · filed 2026-08-06 | -$6.05M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$850.00K 10-Q · filed 2025-11-03 | -$1.75M derived: sum of 2 quarters · filed 2026-08-06 | -$3.40M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | -$900.00K 10-Q · filed 2026-08-06 | -$2.55M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$1.65M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$4.75M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |